Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by XTX Topco Ltd

XTX Topco Ltd lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 43.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,722 shares of the company's stock after selling 2,818 shares during the quarter. XTX Topco Ltd's holdings in Medpace were worth $1,237,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. R Squared Ltd acquired a new position in Medpace in the 4th quarter valued at $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of Medpace in the fourth quarter valued at about $31,000. Jones Financial Companies Lllp lifted its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC boosted its position in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares during the last quarter. Finally, Assetmark Inc. grew its stake in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Down 0.1 %

Shares of MEDP traded down $0.22 during trading on Friday, reaching $296.28. 698,291 shares of the company traded hands, compared to its average volume of 326,249. The stock has a 50-day simple moving average of $318.52 and a 200-day simple moving average of $333.25. The stock has a market cap of $8.96 billion, a PE ratio of 23.46, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a twelve month low of $272.00 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MEDP. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Truist Financial reduced their price objective on Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and dropped their target price for the company from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partners began coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Finally, Robert W. Baird boosted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $357.50.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.